Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8982627 | 0.85 | CA12 (0.61) | CA12CA9TSHRSMN1; SMN2EPHX2 | |
| SCHEMBL10692989 | 0.84 | CA12 (0.50) | CA12CA9EPHX2THRB | |
| SCHEMBL9619019 | 0.84 | CA12 (0.50) | CA12CA9TSHRSMN1; SMN2EPHX2 | |
| SCHEMBL10625337 | 0.83 | TSHR (0.45) | CA12CA9TSHRSMN1; SMN2CA2 | |
| SCHEMBL27563289 | 0.82 | CA12 (0.47) | CA12CA9TSHR | |
| SCHEMBL11248541 | 0.82 | TSHR (0.44) | CA12CA9TSHRSMN1; SMN2CA2 | |
| SCHEMBL12472341 | 0.81 | CA12 (0.61) | CA12CA9TSHRSMN1; SMN2EPHX2 | |
| SCHEMBL8666072 | 0.81 | CA12 (0.47) | CA12CA9TSHRSMN1; SMN2EPHX2 | |
| Hexane SCHEMBL27656302 | 0.81 | TSHR (0.50) | CA12CA9TSHR | |
| SCHEMBL7784111 | 0.80 | CA12 (0.52) | CA12CA9TSHRSMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473249-B2 | Aromatic compounds and pharmaceutical uses thereof | BASF AS (NO) | 2025-11-18 | — | — | US | disclosed |
| US-20210380521-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | BASF AS (NO) | 2021-12-09 | — | — | US | disclosed |
| US-20210380521-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | BASF AS (NO) | 2021-12-09 | — | — | US | disclosed |
| EP-3864001-A1 | ROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | BASF AS (NO) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473249-B2 | Aromatic compounds and pharmaceutical uses thereof | GLS2, FFAR3, SLC10A1 | CA12 1054/4885CA9 1011/4885TSHR 1202/4885 |
| US-20210380521-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GLS2, FFAR3, SLC10A1 | CA12 1054/4885CA9 1011/4885TSHR 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.